Literature DB >> 25952280

Should PET/CT be implemented in the routine imaging work-up of locally advanced head and neck squamous cell carcinoma? A prospective analysis.

Jon Cacicedo1, Iratxe Fernandez, Olga Del Hoyo, Ainara Dolado, Javier Gómez-Suarez, Eduardo Hortelano, Aintzane Sancho, Jose I Pijoan, Julio Alvarez, Jose M Espinosa, Ayman Gaafar, Pedro Bilbao.   

Abstract

PURPOSE: The objective of this study was to determine the incremental staging information provided by positron emission tomography/computed tomography (PET/CT) and its impact on management plans in patients with untreated stage III-IV head and neck squamous cell carcinoma (HNSCC).
METHODS: We prospectively studied, between September 2011 and February 2013, 84 consecutive patients [median age 63.5 years (39-84); 73 men] with histologically confirmed HNSCC. First, based on a conventional work-up (physical examination, CT imaging of the head, neck and chest), the multidisciplinary Head and Neck Tumour Board documented the TNM stage and a management plan for each patient, outlining the modalities to be used, including surgery, radiation therapy (RT), chemotherapy or a combination. After release of the PET/CT results, new TNM staging and management plans were agreed on by the multidisciplinary Tumour Board. Any changes in stage or intended management due to the PET/CT findings were then analysed. The impact on patient management was classified as: low (treatment modality, delivery and intent unchanged), moderate (change within the same treatment modality: type of surgery, radiation technique/dose) or high (change in treatment intent and/or treatment modality → curative to palliative, or surgery to chemoradiation or detection of unknown primary tumour or a synchronous second primary tumour). TNM stage was validated by histopathological analysis, additional imaging or follow-up. Accuracy of the conventional and PET/CT-based staging was compared using McNemar's test.
RESULTS: Conventional and PET/CT stages were discordant in 32/84 (38 %) cases: the T stage in 2/32 (6.2 %), the N stage in 21/32 (65.7 %) and the M stage 9/32 (28.1 %). Patient management was altered in 22/84 (26 %) patients, with a moderate impact in 8 (9.5 %) patients and high impact in 14 (16.6 %) patients. PET/CT TNM classification was significantly more accurate (92.5 vs 73.7 %) than conventional staging with a p value < 0.001 (McNemar's test).
CONCLUSION: PET/CT should be implemented in the routine imaging work-up of stage III-IV HNSCC.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25952280     DOI: 10.1007/s00259-015-3071-0

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  32 in total

1.  Neck dissection classification update: revisions proposed by the American Head and Neck Society and the American Academy of Otolaryngology-Head and Neck Surgery.

Authors:  K Thomas Robbins; Garry Clayman; Paul A Levine; Jesus Medina; Roy Sessions; Ashok Shaha; Peter Som; Gregory T Wolf
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2002-07

Review 2.  Evidence-based guideline recommendations on the use of positron emission tomography imaging in head and neck cancer.

Authors:  J Yoo; S Henderson; C Walker-Dilks
Journal:  Clin Oncol (R Coll Radiol)       Date:  2012-09-26       Impact factor: 4.126

3.  The value of (18)F-FDG PET/CT for the detection of distant metastases in high-risk patients with head and neck squamous cell carcinoma.

Authors:  Stephan K Haerle; D T Schmid; N Ahmad; T F Hany; S J Stoeckli
Journal:  Oral Oncol       Date:  2011-06-11       Impact factor: 5.337

4.  Screening for distant metastases in patients with head and neck cancer: is chest computed tomography sufficient?

Authors:  Jolijn Brouwer; Remco de Bree; Otto S Hoekstra; Richard P Golding; Johannes A Langendijk; Jonas A Castelijns; C René Leemans
Journal:  Laryngoscope       Date:  2005-10       Impact factor: 3.325

Review 5.  The role of fluorodeoxyglucose positron emission tomography in cervical lymph node metastases from an unknown primary tumor.

Authors:  Kyle E Rusthoven; Mary Koshy; Arnold C Paulino
Journal:  Cancer       Date:  2004-12-01       Impact factor: 6.860

6.  Chest CT and whole-body 18F-FDG PET are cost-effective in screening for distant metastases in head and neck cancer patients.

Authors:  Carin A Uyl-de Groot; Asaf Senft; Remco de Bree; C René Leemans; Otto S Hoekstra
Journal:  J Nucl Med       Date:  2010-02       Impact factor: 10.057

7.  Positron emission tomography with [18F]fluorodeoxyglucose improves staging and patient management in patients with head and neck squamous cell carcinoma: a multicenter prospective study.

Authors:  Max Lonneux; Marc Hamoir; Hervé Reychler; Philippe Maingon; Christian Duvillard; Gilles Calais; Boumédiène Bridji; Laurence Digue; Michel Toubeau; Vincent Grégoire
Journal:  J Clin Oncol       Date:  2010-02-01       Impact factor: 44.544

8.  Occult Primary Head and Neck Squamous Cell Carcinoma: Utility of Discovering Primary Lesions.

Authors:  Kara S Davis; J Kenneth Byrd; Vikas Mehta; Simon I Chiosea; Seungwon Kim; Robert L Ferris; Jonas T Johnson; Umamaheswar Duvvuri
Journal:  Otolaryngol Head Neck Surg       Date:  2014-05-08       Impact factor: 3.497

9.  (18)F-FDG-PET/CT versus panendoscopy for the detection of synchronous second primary tumors in patients with head and neck squamous cell carcinoma.

Authors:  Stephan K Haerle; Klaus Strobel; Thomas F Hany; Daniel Sidler; Sandro J Stoeckli
Journal:  Head Neck       Date:  2010-03       Impact factor: 3.147

10.  PET changes management and improves prognostic stratification in patients with head and neck cancer: results of a multicenter prospective study.

Authors:  Andrew M Scott; Dishan H Gunawardana; Dylan Bartholomeusz; Jayne E Ramshaw; Peter Lin
Journal:  J Nucl Med       Date:  2008-09-15       Impact factor: 10.057

View more
  13 in total

1.  Positron Emission Tomography/Computed Tomography in Evaluation of the Clinically N0 Neck in Head and Neck Squamous Cell Carcinoma.

Authors:  Robert L Ferris; John D Cramer; Barton F Branstetter Iv
Journal:  J Clin Oncol       Date:  2019-05-31       Impact factor: 44.544

2.  Multicenter Trial of [18F]fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Staging of Head and Neck Cancer and Negative Predictive Value and Surgical Impact in the N0 Neck: Results From ACRIN 6685.

Authors:  Val J Lowe; Fenghai Duan; Rathan M Subramaniam; JoRean D Sicks; Justin Romanoff; Twyla Bartel; Jian Q Michael Yu; Brian Nussenbaum; Jeremy Richmon; Charles D Arnold; David Cognetti; Brendan C Stack
Journal:  J Clin Oncol       Date:  2019-02-15       Impact factor: 44.544

Review 3.  Role of fluorine-18 fluorodeoxyglucose PET/CT in head and neck oncology: the point of view of the radiation oncologist.

Authors:  Jon Cacicedo; Arturo Navarro; Olga Del Hoyo; Alfonso Gomez-Iturriaga; Filippo Alongi; Jose A Medina; Olgun Elicin; Andrea Skanjeti; Francesco Giammarile; Pedro Bilbao; Francisco Casquero; Berardino de Bari; Alan Dal Pra
Journal:  Br J Radiol       Date:  2016-08-02       Impact factor: 3.039

4.  PET/CT prior to salvage surgery in recurrent head and neck squamous cell carcinoma.

Authors:  A Nøhr; S B Gram; B Charabi; J F Tvedskov; I Wessel; J Friborg; K Håkansson; C von Buchwald; B M Fischer; Jacob H Rasmussen
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-07-11       Impact factor: 2.503

5.  18F-Fluorodeoxyglucose-PET/CT in locally advanced head and neck cancer can influence the stage migration and nodal radiation treatment volumes.

Authors:  Rosario Mazzola; Pierpaolo Alongi; Francesco Ricchetti; Alba Fiorentino; Sergio Fersino; Niccolò Giaj-Levra; Matteo Salgarello; Filippo Alongi
Journal:  Radiol Med       Date:  2017-08-28       Impact factor: 3.469

Review 6.  Testing the Timing: Time Factor in Radiation Treatment for Head and Neck Cancers.

Authors:  Muhammad M Fareed; Rizwan Ishtiaq; Thomas J Galloway
Journal:  Curr Treat Options Oncol       Date:  2018-03-12

7.  Prognostic value of maximum standardized uptake value measured by pretreatment 18F-FDG PET/CT in locally advanced head and neck squamous cell carcinoma.

Authors:  J Cacicedo; I Fernandez; O Del Hoyo; A Navarro; A Gomez-Iturriaga; J Ignacio Pijoan; L Martinez-Indart; J Escudero; J Gomez-Suarez; R Ortiz de Zarate; J Fernando Perez; P Bilbao; D Rades
Journal:  Clin Transl Oncol       Date:  2017-05-24       Impact factor: 3.405

8.  Utility of 18F-FDG-PET/CT in patients suspected of paraneoplastic neurological syndrome: importance of risk classification.

Authors:  F J Pena Pardo; A M García Vicente; M Amo-Salas; J F López-Fidalgo; J A Garrido Robles; J Á de Ayala Fernández; P Del Saz Saucedo; M Muñoz Pasadas; A Soriano Castrejón
Journal:  Clin Transl Oncol       Date:  2016-05-02       Impact factor: 3.405

9.  Impact of PET/CT on Staging and Treatment of Advanced Head and Neck Squamous Cell Carcinoma.

Authors:  Jeffery B Jorgensen; Russell B Smith; Andrew Coughlin; William C Spanos; Michele M Lohr; Steven M Sperry; Oleg Militsakh; Robert P Zitsch; Bevan Yueh; Laura M Dooley; Aru Panwar; Tabitha L I Galloway; Nitin A Pagedar
Journal:  Otolaryngol Head Neck Surg       Date:  2018-08-21       Impact factor: 3.497

10.  Integration of 18-FDG PET/CT in the Initial Work-Up to Stage Head and Neck Cancer: Prognostic Significance and Impact on Therapeutic Decision Making.

Authors:  Jean-Christophe Leclere; Olivier Delcroix; Jean Rousset; Gerald Valette; Philippe Robin; Catherine Guezennec; Romain Le Pennec; Dorothy M Gujral; Maelig Abgral; Luc Ollivier; Remi Marianowski; Pierre-Yves Salaun; Ulrike Schick; Ronan Abgral
Journal:  Front Med (Lausanne)       Date:  2020-06-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.